Polaris Group appointed Chien-Hsing Chang, Vice President of R&D, IMMUNOMEDICS Inc. as Chief Strategy Officer effective June 20, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
71 TWD | -0.70% | +3.20% | -6.08% |
05-15 | Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA | CI |
05-14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.08% | 1.64B | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- 6550 Stock
- News Polaris Group
- Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023